Publications & Posters

Contributing to and advancing the scientific dialogue

June 2023

LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

June 2023

Healthcare resource use for pediatric low-grade glioma care: a cohort of linked electronic health records and claims data

May 2023

Phase 1 study of the pan RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

May 2023

Chart audit in pediatric low-grade glioma: molecular testing and treatment patterns

May 2023

pLGG disease burden and healthcare utilization: linked claims and EHR data study

April 2023

Clinical activity of the type II pan-RAF inhibitor tovorafenib in BRAF-fusion melanoma

November 2022

FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors

November 2022

LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric patients with newly diagnosed low-grade glioma harboring an activating RAF alteration

See our progress in motion.